• Trinity Biotech announced successful clinical study results for an enhanced version of its EpiCapture prostate cancer test that incorporates an enhanced machine learning risk prediction algorithm.
• The upgraded urine liquid biopsy test integrates additional patient features, including patient ethnicity alongside DNA biomarkers, to generate individualized risk prediction scores.
• Performance was evaluated in an independently conducted clinical study of approximately 750 patient samples, and results showed clinical accuracy (Area Under the Curve, AUC) of 85%.
• Findings have not yet been presented in a journal and will be submitted for publication in a peer reviewed oncology journal.
• Commercialization plans call for offering EpiCapture as a proprietary Laboratory Developed Test (LDT) through the company’s New York State Department of Health certified diagnostics reference laboratory.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Trinity Biotech plc published the original content used to generate this news brief via EDGAR, the Electronic Data Gathering, Analysis, and Retrieval system operated by the U.S. Securities and Exchange Commission (Ref. ID: 0001178913-26-001700), on March 25, 2026, and is solely responsible for the information contained therein.